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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is associated with abnormal inflammatory responses
and structural alterations of the airways, lung parenchyma and pulmonary vasculature. Since Pentraxin-3 (PTX3) is a
tuner of inflammatory responses and is produced by endothelial and inflammatory cells upon stimuli such as
interleukin-1b (IL-1b), we hypothesized that PTX3 is involved in COPD pathogenesis.
Methods and Results: We evaluated whether cigarette smoke (CS) triggers pulmonary and systemic PTX3
expression in vivo in a murine model of COPD. Using immunohistochemical (IHC) staining, we observed PTX3
expression in endothelial cells of lung venules and veins but not in lung arteries, airways and parenchyma.
Moreover, ELISA on lung homogenates and semi-quantitative scoring of IHC-stained sections revealed a significant
upregulation of PTX3 upon subacute and chronic CS exposure. Interestingly, PTX3 expression was not enhanced
upon subacute CS exposure in IL-1RI KO mice, suggesting that the IL-1 pathway is implicated in CS-induced
expression of vascular PTX3. Serum PTX3 levels increased rapidly but transiently after acute CS exposure.
To elucidate the functional role of PTX3 in CS-induced responses, we examined pulmonary inflammation, protease/
antiprotease balance, emphysema and body weight changes in WT and Ptx3 KO mice. CS-induced pulmonary
inflammation, peribronchial lymphoid aggregates, increase in MMP-12/TIMP-1 mRNA ratio, emphysema and failure
to gain weight were not significantly different in Ptx3 KO mice compared to WT mice. In addition, Ptx3 deficiency
did not affect the CS-induced alterations in the pulmonary (mRNA and protein) expression of VEGF-A and FGF-2,
which are crucial regulators of angiogenesis.
Conclusions: CS increases pulmonary PTX3 expression in an IL-1 dependent manner. However, our results suggest
that either PTX3 is not critical in CS-induced pulmonary inflammation, emphysema and body weight changes, or
that its role can be fulfilled by other mediators with overlapping activities.
Background
Chronic obstructive pulmonary disease (COPD), a pri-
marily cigarette smoke (CS)-induced disease, is a major
cause of chronic morbidity and mortality worldwide
[1,2]. COPD is characterized by progressive and largely
irreversible airflow limitation caused by obstructive
bronchiolitis and emphysema which are associated with
an abnormal inflammatory response of the lungs to
noxious particles or gases [2]. Several mechanisms are
involved in the disease pathogenesis: inflammatory cell
recruitment to the lungs, imbalance between proteolytic
and anti-proteolytic activity, oxidative stress and apopto-
sis/proliferation imbalance [3]. Besides major abnormal-
ities in the airways, changes in pulmonary vessels
represent an important component of COPD pathology
[4]. Moreover, some patients with COPD exhibit low-
grade systemic inflammation that is often associated
with extrapulmonary (systemic) effects, such as weight
loss and cardiovascular disease [5-7]. However, the precise
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molecular mechanisms whereby CS triggers abnormal pul-
monary and systemic manifestations remain unclear.
Pentraxins are a superfamily of soluble pattern recog-
nition receptors characterized by a cyclic multimeric
structure [8]. Pentraxin 3 (PTX3), the prototypic long
pentraxin which is highly conserved between mice and
humans, differs from short pentraxins (C-reactive pro-
tein [CRP] and serum amyloid P [SAP]) in many aspects
such as cellular source, regulation of the production and
function [8]. PTX3 is, in contrast with the hepatically
derived short pentraxins, mainly produced by inflamma-
tory cells [9] and endothelial cells [10,11], which allows
it to act locally at sites of infection and inflammation. It
is produced in response to the pro-inflammatory cyto-
kines IL-1b and tumor necrosis factor-a (TNF-a) and
microbial components such as LPS, a component of
gram-negative bacteria, which is also present in CS
[10-12].
PTX3 has major roles in innate immunity and inflam-
mation [8]. It interacts with specific pathogens such as
Klebsiella pneumoniae [13], and apoptotic cells [14],
thereby contributing to their clearance. Patients with
COPD are frequently colonized with bacteria in the
lower airways [15] and several reports described cell
death of structural cells such as epithelial cells [16] and
endothelial cells [17] in human emphysema. Moreover,
PTX3 mediates angiogenesis by influencing Fibroblast
Growth Factor-2 (FGF-2) activity [18] and is a marker
of endothelial dysfunction reflecting vascular inflamma-
tory state in many diseases such as small vessel vasculi-
tis [19]. Importantly, exposure to environmental CS
induces pulmonary angiogenesis in mice [20]. PTX3 is
also described as an early indicator of acute myocardial
infarction (AMI) in humans [21] and its cardioprotective
role, by modulating the reperfusion-associated inflam-
matory response and tissue damage, is dependent on the
IL-1RI pathway, as determined in a mouse model of
AMI [22]. PTX3 appears to be a stronger predictor of
cardiovascular mortality than C-reactive protein (CRP),
a short pentraxin elevated in patients with COPD [23].
Therefore, we put forward the hypothesis that PTX3
plays a critical role in COPD, a chronic inflammatory
disease where multiple inflammatory and resident cells
are involved and multiple organs are affected.
In this study, we evaluated the impact of CS on pul-
monary PTX3 expression in wild-type (WT) mice. We
next investigated PTX3 expression in lungs of mice defi-
cient for the IL-1 pathway (IL-1RI KO mice) to eluci-
date the molecular mechanism. We also examined the
in vivo functional role of PTX3, by measuring pulmon-
ary inflammation including lymphoid aggregate forma-
tion and emphysema in WT and Ptx3 KO mice upon
CS exposure. We next examined if CS triggers systemic
PTX3 expression and if PTX3 deficiency affects CS-
induced systemic manifestations such as body weight
changes.
Methods
Animals
Homozygous breeding pairs of C57BL/6J WT mice and
IL-1RI knockout (KO) mice (B6.129S7-Il1r1tm1Imx) were
obtained from The Jackson Laboratory (Bar Harbor,
ME, USA) and bred in the animal facility at Faculty of
Medicine and Health Sciences, Ghent University (Ghent,
Belgium). Additionally, mice with a heterozygous tar-
geted mutation in the Ptx3 gene, backcrossed 11 genera-
tions onto the C57BL/6 background, were obtained
from A. Mantovani (Istituto Clinico Humanitas IRCCS,
Rozzano, Milan, Italy) [13]. Heterozygous breeding pairs
were bred in the animal facility and the offspring was gen-
otyped using a protocol described by C. Garlanda et al.
[13]. Male homozygous Ptx3 KO mice and homozygous
wild-type (WT) littermates were used for the described
experiments. Animals of 7-13 weeks were divided into
age-and body weight-matched groups and maintained in
standard conditions under a 12 h light-dark cycle,
provided a standard diet (Pavan, Brussels, Belgium) and
chlorinated tap water ad libitum. All in vivo manipulations
were approved by the local Ethics Committee for animal
experimentation of the Faculty of Medicine and Health
Sciences, Ghent University.
Cigarette smoke (CS) exposure
Groups of 10 mice were exposed to CS, as described
previously [24]. Briefly, the animals received mainstream
CS of 5 reference cigarettes (2R4F without filter; Univer-
sity of Kentucky, Lexington, KY, USA) 4 times a day
with 30-min smoke-free intervals. An optimal smoke/air
ratio of 1/6 was obtained. The mice were exposed for 3
days (acute), 4 weeks (subacute) or 24 weeks (chronic).
The control groups were exposed to room air. The body
weight of the mice were measured at the beginning and
the end of the chronic experiment. Immediately after
smoke exposure, carboxyhaemoglobin (COHb) fractions
in blood were measured in CS-exposed (8.35 ± 0.47%)
and air-exposed mice (0.65 ± 0.25%) (n = 4).
Collection of serum
At 1 h, 6 h or 24 h after the last exposure, mice were
sacrificed by an i.p. injection of pentobarbital (CEVA-
Sanofi, Paris, France). Subsequently, blood was sampled
from the orbital sinus and processed for the collection
of serum.
Bronchoalveolar lavage (BAL)
Bronchoalveolar lavage was performed as previously
described [25]. Briefly, lungs were first lavaged using 3 times
300 μl HBSS, free of Ca2+ and Mg2+ and supplemented
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with 1% BSA, followed by 3 times 1 ml HBSS supple-
mented with 0.6 mM EDTA, via a tracheal cannula.
The six lavage fractions were pooled, centrifuged, and
the cell pellet was finally resuspended in 200 μl buffer
(PBS supplemented with 1% BSA, 5 mM EDTA and
0.1% sodium azide). Subsequently, total cell counts
were obtained using a Bürker chamber and differential
cell counts (on at least 400 cells) were performed on
cytocentrifuged preparations after May-Grünwald
(Sigma-Aldrich, St. Louis, MO) and Giemsa staining
(VWR, West Chester, PA, USA). Discrimination of
neutrophils was obtained based on standard morpholo-
gic criteria. Flow cytometric analysis of BAL cells was
performed to enumerate macrophages, dendritic cells
(DCs) and CD4+ and CD8+ T-lymphocytes.
Lung harvest and preparation of lung single-cell
suspensions
Following BAL, the pulmonary and systemic circulation
was rinsed with saline, supplemented with 5 mM EDTA.
The left lung was excised for histology, as previously
described [26]. The right lung was used for the prepara-
tion of lung homogenate (middle lobe) and single-cell
suspension (major lobe), as described previously [26].
Briefly, the lung was thoroughly minced, digested, sub-
jected to red blood cell lyses, passed through a 50 μm
cell strainer and kept on ice until labelling. Cell count-
ing occurred with a Z2 particle counter (Beckman-
Coulter Inc., Fullerton, CA, USA).
Labelling of BAL cells and lung single-cell suspension for
flow cytometry
The cells were first incubated with FcR blocking anti-
body (anti-CD16/CD32, clone 2.4G2) to reduce nonspe-
cific binding. Secondly, the labelling reactions were
performed to discriminate DCs, macrophages and
T-lymphocytes. All reactions were performed on ice
using monoclonal Abs obtained from BD Pharmingen
(San Diego, CA, USA). The DCs and macrophages were
discriminated using the methodology described by Ver-
maelen and Pauwels [27]. Briefly, DCs were characterized
as CD11c-bright (APC-conjugated anti-CD11c; HL3), low
autofluorescent and MHC class II-high (PE-conjugated
anti-I-A[b]; AF6-120.1) population. Macrophages are iden-
tified as the CD11c-bright and high autofluorescent cell
population. Mouse T cell subpopulations in lung single
cell-suspensions were identified by the following antibo-
dies (Abs): FITC-conjugated anti-CD4 (GK1.5), FITC-
conjugated anti-CD8 (53-6.7), APC-conjugated anti-CD3
(145-2C11) and PE-conjugated anti-CD69 (H1.2F3),
a marker for activation of T-lymphocytes. Finally, all
samples were incubated with 7-Amino-actinomycin D
for exclusion of dead cells (BD Pharmingen, San Diego,
CA, USA).
Flow cytometry data acquisition was performed on a
dual-laser FACS Calibur™flow cytometer running Cell-
Quest™software (BD Biosciences, San Diego, CA, USA).
FlowJo Software (Tree Star Inc., Ashland, OR, USA) was
used for data analysis.
Preparation of lung tissue homogenate
The middle lobe of the right lung was snap-frozen (in
liquid nitrogen) and stored at -80°C until further analy-
sis. The lobes were transferred to tubes containing 1 ml
T-PER Tissue Protein Extraction Reagent containing
Halt™Protease Inhibitor Cocktail Kit (Thermo Fisher
Scientific, Waltham, MA, USA) and homogenized on ice
using TissueRuptor (Qiagen, Hilden, Germany). The
homogenates were centrifuged (10000 × g for 5 min at
4°C) and the middle layer was transferred to microcen-
trifuge tubes. Total protein concentration was measured
using the Bradford Protein Assay (Bio-Rad Laboratories,
Hercules, CA, USA). Lung tissue homogenates were
diluted with T-PER containing Cocktail Kit to a final
protein concentration of 500 μg/ml.
PTX3, VEGF-A and FGF-2 ELISA
We determined PTX3 levels (BAL fluid, lung homoge-
nate and serum), VEGF-A (lung homogenate) and FGF-
2 levels (lung homogenate) using commercially available
ELISA kits with a sensitivity of 12 pg/ml, 3 pg/ml and 8
pg/ml respectively (R&D systems, Minneapolis, MN,
USA). ELISA was performed following the manufac-
turer’s instructions.
Histology of the lung
The left lung was fixed by gentle infusion of fixative
(4% paraformaldehyde) through the tracheal cannula
[24]. After excision, the lung was immersed in a fresh
fixative for 2 h. The lung lobe was embedded in paraf-
fin and cut into 3 μm transverse sections, followed by
immunohistochemical and chemical staining. Photo-
micrographs were captured using KS400 image analyze
platform (Zeiss, Oberkochen, Germany) and analyzed
quantitatively.
Immunohistochemistry and quantification of pentraxin-3
To evaluate pentraxin-3 expression in lung tissue, sec-
tions were subjected to PTX3 staining using anti-PTX3
antibody. First, tissue sections were incubated with
Boehringer blocking agent with 0.3% triton and primary
antibody anti-PTX3 (Alexis Biochemicals, Farmingdale,
NY) or isotype rabbit Ig (Abcam, Cambridge, UK). Sub-
sequently, the slides were incubated with PowerVision
poly-horse radish peroxidase (HRP)-anti-rabbit (Immu-
novision Technologies, Burlingame, CA, USA) and
stained with 3,3’-diaminobenzidine ([DAB] Dako,
Glostrup, Denmark). Sections were counterstained with
Pauwels et al. Respiratory Research 2010, 11:134
http://respiratory-research.com/content/11/1/134
Page 3 of 15
hematoxylin and mounted using mounting medium
(Thermo Fisher Scientific). Photomicrographs were
taken of all PTX3 positive veins and the area of the
endothelial cells was marked manually on the digital
representation of the vein using KS400 image analyze
platform (Zeiss). The surface area covered by the stain
was measured by the software (KS400) and its value was
normalized to the length of internal perimeter (P) of the
vein.
Quantification of peribronchial lymphoid aggregates
To evaluate the presence of lymphoid aggregates in lung
tissue after chronic smoke exposure, lung sections were
subjected to double staining for CD3 (T-lymphocyte
marker) and B220/CD45R (B-lymphocyte marker), as
described previously [28]. Briefly, the sections were first
incubated with Boehringer blocking agent with 0.3% tri-
ton and primary antibody anti-CD3 (Dako) or isotype
rabbit IgG1, (Abcam). Subsequently, the slides were
incubated with PowerVision poly-HRP-anti-rabbit
(Immunovision Technologies) and stained with DAB
(Dako).
Secondly, the sections were stained with anti-B220/
CD45R biotin (RA3-6B2) or isotype IgG2a, biotin after
Boehringer blocking with 0.3% triton. Both antibodies
for the second step were purchased from BD Pharmin-
gen. Subsequently, the slides were incubated with
rat-on-mouse alkaline phosphatase (AP)-polymer kit
(Biocare Medical, Concord, CA, USA) and stained with
Vector Blue (Vector Laboratories, Burlingame, CA,
USA). Thirdly, sections were counterstained with 0.5%
methylgreen (Sigma-Aldrich) and mounted using Vecta-
mount mounting medium (Vector Laboratories).
Lymphoid aggregates, defined as dense accumulations
of at least 50 cells, were counted in the tissue area sur-
rounding the airways (airway perimeter 0-2000 μm).
Results were expressed as counts relative to the num-
bers of airways per lung section.
Emphysema measurement
Emphysema, a structural disorder of the lung parench-
yma characterized by airspace enlargement, is quantified
after 24 weeks of air or CS exposure by measurement of
the mean linear intercept (Lm), as described in detail
previously [24,29,30], using image analysis software
(Image J1.36b).
RNA preparation and real-time RT-PCR
RNA was extracted from lung tissue using the miR-
Neasy Mini kit (Qiagen), following manufacturer’s
instructions. Expression of VEGF-A, FGF-2, MMP-12 and
TIMP-1 mRNA, relative to HPRT mRNA (Hypoxanthine
guanine phosphoribosyl transferase, a reference gene)
was determined by real-time RT-PCR using the Taq-
Man Gene Expression assays (Applied Biosystems, Fos-
ter City, CA, USA) including the respective primers/
fluorogenic probe mix specific for each molecule. Real-
time RT-PCR reactions were set up in triplicate using
identical reverse transcription and amplification condi-
tions for each of the molecules and the reference gene.
Reverse transcription was performed at 48°C for 30
minutes. Amplification conditions consisted of: 10 min-
utes at 95 °C, 45 cycles of 10 s at 95 °C and 15 s at 60
°C. Reaction samples had a final volume of 20 μl con-
sisting of Universal Master mix, RNase inhibitor, MuLV
Rtase, the specific primer/probe mix (Applied Biosys-
tems) and 10 ng total RNA. Amplifications were per-
formed, using a LightCycler480 detection system
(Roche, Basel, Switzerland).
Statistical analysis
Statistical analysis was performed with Sigma Stat soft-
ware (SPSS 15.0, Chicago, IL, USA) using non-
parametric tests (Kruskall-Wallis; Mann-Whitney U).
Reported values are expressed as mean ± SEM. P-values
< 0.05 were considered to be significant.
Results
Cigarette smoke (CS) exposure increases expression of
pentraxin-3 in pulmonary endothelial cells
We evaluated pentraxin-3 (PTX3) expression in bronch-
oalveolar lavage (BAL) fluid and lung tissue of WT mice
at 24 h after 3 days (acute), 4 weeks (subacute) or 24
weeks (chronic) air or CS exposure. PTX3 levels were
below the detection limit in BAL fluid of both air-and
CS-exposed mice, as measured by ELISA (data not
shown). In contrast, PTX3 was detectable in lung tissue
homogenates at all timepoints and increased signifi-
cantly upon 4 weeks and 24 weeks of CS exposure (Fig-
ure 1). In order to localize pulmonary PTX3, we
performed immunohistochemical staining on lung tissue
sections using an antibody specific for PTX3. PTX3 was
localized in endothelial cells of veins and venules but
not in endothelial cells of arteries or other structural
lung cells (Figure 2A and 2B). No expression of PTX3
was observed in lungs of Ptx3 KO mice (Figure 2C and
2D). Next, we quantified PTX3 expression in pulmonary
veins using the KS400 image analysis platform. In accor-
dance with the ELISA for PTX3 in lung homogenate,
acute CS exposure did not affect PTX3 expression in
the pulmonary veins, while subacute and chronic CS
exposure significantly upregulated PTX3 in veins of the
lung by two-fold, compared to air-exposed animals
(Figure 3).
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CS-induced pulmonary PTX3 expression depends on the
IL-1RI pathway
Since PTX3 has been identified as an IL-1 inducible
gene in endothelial cells [10], we examined PTX3
expression in air-and CS-exposed IL-1RI KO mice. In
contrast with the CS-induced increase of PTX3 in
WT mice, PTX3 levels in lung homogenates of IL-1RI
KO mice were not affected by subacute CS exposure
(Figure 4A). Accordingly, CS exposure for 4 weeks did
not increase PTX3 expression in veins of IL-1RI KO
mice, as analyzed quantitatively on lung sections (Fig-
ure 4B). This indicates that the IL-1 pathway regulates
CS-induced upregulation of pulmonary vascular
PTX3.
Pulmonary levels of VEGF-A and FGF-2 are affected by CS
exposure in a PTX3 independent manner
Since CS exposure affected PTX3 expression in pul-
monary veins, we studied growth factors which regulate
vascular cell growth and survival, as markers of
endothelial function and dysfunction in WT and Ptx3
KO mice. CS significantly downregulated mRNA levels
of VEGF-A and FGF-2 at both subacute and chronic
timepoints (Table 1). Exposure to CS also significantly
affected protein levels of VEGF-A (downregulation) and
FGF-2 (upregulation), as documented in Table 1. Inter-
estingly, CS-induced mRNA and protein levels of these
growth factors were not affected by PTX3 deficiency
(Table 1).
CS-induced pulmonary inflammation is not affected in
Ptx3 KO mice
PTX3 is a pattern recognition receptor modulating cel-
lular immunity. Therefore, we compared the CS-induced
pulmonary inflammation between WT mice and Ptx3
KO mice. Both subacute and chronic CS exposure sig-
nificantly increased the total numbers of neutrophils,
dendritic cells (DCs) and CD4+ and CD8+ T-lympho-
cytes in BAL fluid of WT and Ptx3 KO mice (Figure 5
and 6). The absolute number of macrophages was not
affected by CS exposure or PTX3 deficiency (Figure 5
and 6). However at both timepoints, the CS-induced
pulmonary inflammation was not affected by PTX3 defi-
ciency (Figure 5 and 6). Also in lung homogenates,
CS-induced accumulation of macrophages, DCs and
CD4+ and CD8+ T-lymphocytes was not significantly
different between WT and Ptx3 KO mice (data not
shown). CS-induced peribronchial lymphoid aggregate for-
mation was also not affected by PTX3 deficiency (Figure 7).
Emphysema in CS-exposed WT and Ptx3 KO mice
Since PTX3 maintains homeostatic equilibrium in the
local immune responses and dysregulation of lung
homeostasis can contribute to the pathogenesis of pul-
monary emphysema, we examined the mean linear
intercept (Lm), a measure of alveolar space enlargement,
in WT and Ptx3 KO mice (N = 8 animals/group). In
WT mice, Lm increased significantly by 9.4% upon 24
weeks of CS exposure (air: 39.2 ± 0.8 μm vs. CS: 42.9 ±
1.1 μm; p < 0.05; Figure 8A and 8B). In Ptx3 KO mice,
Lm increased by 5,5% upon CS exposure (air: 39.7 ± 0.9
μm vs. CS: 41.9 ± 1.1 μm; p > 0.05; Figure 8C and 8D).
Importantly, there was no significant difference in air-
space enlargement, as measured by Lm, between CS-
exposed WT and Ptx3 KO mice (P = 0.54).
Pulmonary protease/antiprotease imbalance upon CS
exposure is unaffected by PTX3 deficiency
Subacute and chronic CS exposure significantly upregu-
lated matrix metalloproteinase-12 (MMP-12) and tissue
inhibitor of matrix metalloproteinase (TIMP-1) in lung
tissue of WT and Ptx3 KO mice, as measured by qRT-
PCR (Table 2). However, CS-induced upregulation was
unaffected by the genotype (Table 2). Interestingly, in
air-exposed mice, the protease/antiprotease balance was
in favor of the antiprotease, whereas the opposite
occurred in CS-exposed mice (air-exposed mice: MMP-
12/TIMP-1 ratio < 1; CS-exposed mice: MMP-12/
TIMP-1 ratio > 1).
Rapid but transient upregulation of systemic pentraxin-3
upon CS exposure
First, we measured serum PTX3 levels of WT mice at
24 h after 3 days (acute), 4 weeks (subacute) or 24
weeks (chronic) air or CS exposure, by ELISA. PTX3
was detectable in serum, but not elevated from baseline
levels at 24 h after last smoke exposure at all timepoints
(data not shown). Secondly, since PTX3 reacts as an
acute phase protein which is rapidly released into the
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Figure 1 PTX3 expression in lung homogenate by ELISA. PTX3
protein levels in lung homogenate of WT mice in the acute (3
days), subacute (4 weeks) and chronic (24 weeks) experiment, as
measured by ELISA. Data are expressed as mean ± SEM (N = 8-10
animals/group; *** p < 0.01).
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Figure 2 Pulmonary PTX3 expression by immunohistochemistry (IHC). Photomicrographs of PTX3 stained lung tissue of (A) air-exposed WT
mice, (B) CS-exposed WT mice, (C) air-exposed Ptx3 KO mice and (D) CS-exposed Ptx3 KO mice. All mice were exposed to air or CS for 4 weeks
(subacute). (V: vein; A: artery; AW; airway-magnification 200×).
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blood stream, we performed an acute (3 days) experi-
ment where mice were sacrificied at earlier timepoints
(1 h and 6h) after the last exposure and measured
serum PTX3. Indeed, serum PTX3 levels were signifi-
cantly increased at 1 h and 6 h after the last CS expo-
sure (Figure 9).
CS exposure induces a failure to gain weight
independent of PTX3
In order to evaluate the influence of CS and PTX3 defi-
ciency on body weight, we measured final body weight
of mice who were age-and weight-matched at the begin-
ning of the experiment. In accordance with our previous
study [29], a significant failure to gain weight was
observed in chronically CS-exposed WT mice compared
to air-exposed littermates (air-exposed WT mice: 32.33 ±
0.49 g, CS-exposed WT mice: 25.77 ± 0.61 g, P < 0,001).
Interestingly, Ptx3 KO mice also failed to gain weight
upon chronic CS exposure (air-exposed Ptx3 KO mice:
32.11 ± 0.61 g, CS-exposed Ptx3 KO mice: 27.79 ± 0.58 g,
P < 0,001) and there was no statistical significant differ-
ence between the two genotypes (p > 0,05).
Discussion
In this cigarette smoke model of COPD, we demon-
strated that subacute and chronic CS exposure signifi-
cantly upregulates PTX3 expression in endothelial cells
of lung veins. Moreover, CS-induced PTX3 upregulation
in pulmonary veins is dependent on the IL-1 pathway.
However, PTX3 deficiency does not affect several pul-
monary hallmarks of COPD such as inflammation, peri-
bronchial lymphoid neogenesis and emphysema. Serum
PTX3 levels elevate rapidly but transiently upon CS
exposure, but PTX3 deficiency does not influence
CS-induced weight changes, a systemic manifestation of
COPD.
In this study, we demonstrated that long time CS
exposure significantly upregulates pulmonary PTX3
expression in veins in an IL-1 dependent manner. This
suggests that PTX3 is more downstream than IL-1 in
the inflammatory cascade activated by CS. Recently,
Sapey et al. described a correlation of IL-1b with clinical
aspects of COPD severity [31]. The contribution of
IL-1b in disease pathogenesis was also established using
transgenic and KO mouse models of COPD [32-34].
This suggests that IL-1b may play a critical role in
COPD, by influencing inflammatory responses. Impor-
tantly, IL-1 is also implicated in the induction and main-
tenance of angiogenesis [35]. Taken together, IL-1 might
therefore be involved in tuning vascular inflammatory
responses or angiogenesis in smokers and patients with
COPD via PTX3. However, further studies of angiogen-
esis in vivo are needed to further address this
hypothesis.
Until now, it is unclear whether PTX3 has a protective
or a destructive role in (cardio)vascular pathogenesis.
On one hand, PTX3 has cardioprotective and atheropro-
tective roles, as described in mouse models of acute
myocardial infarction (AMI) and atherosclerosis [22,36],
respectively. On the other hand, a detrimental role was
also ascribed to PTX3 in a mouse model of ischemia
Figure 3 PTX3 expression in lung veins and venules. (A)
Quantification of PTX3 expression in endothelial cell layer of lung
blood vessels. The amount of PTX3 expression measured in the acute
(3 days), subacute (4 weeks) or chronic (24 weeks) experiment was
normalized for the length of internal perimeter of the vein and
expressed as mean ± SEM (N = 8 animals/group; * p < 0.05 and ** p <
0.01). Photomicrographs of PTX3 immunostained veins in lung tissue
upon (B) 3 days air, (C) 3 days CS, (D) 4 weeks air, (E) 4 weeks CS, (F) 24
weeks air and (G) 24 weeks CS exposure. (magnification: 200×).
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Figure 4 Effect of IL-1RI deficiency on cigarette smoke (CS)-induced vascular PTX3 expression. (A) Quantification of PTX3 in lung
homogenate by ELISA. (B) Quantification of PTX3 stained endothelial cell layer of lung blood vessels. The amount of PTX3 expression measured
in a subacute (4 weeks) experiment was normalized for the length of internal perimeter. Photomicrographs of PTX3 immunostained venules of
(C) air-exposed WT, (D) CS-exposed WT, (E) air-exposed IL-1RI KO and (D) CS-exposed IL-1RI KO (magnification: 200×). Data are expressed as
mean ± SEM (N = 8-10 animals/group; * p < 0.05, ** p < 0.01 and *** p < 0.01).
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followed by reperfusion of the superior mesenteric
artery [37]. Since exposure to environmental CS induces
pulmonary angiogenesis in mice [20], we evaluated
VEGF-A and FGF-2-two crucial mediators of angiogen-
esis and markers of endothelial function-to assign if
PTX3 has a protective or destructive role in pulmonary
veins of CS-exposed mice. Camozzi et al. described that
the characteristic N-terminal domain of PTX3 is able to
bind FGF-2, thereby inhibiting the pro-angiogenic activ-
ity of FGF-2 [18]. We observed that FGF-2 protein
levels significantly increased, whereas FGF-2 mRNA
levels decreased, upon 4 weeks and 24 weeks CS expo-
sure. In accordance with our findings, Conte et al.
described that FGF-2 is not activated at the transcrip-
tional level but regulated at the translational level in an
ischemia model [38]. We observed that both VEGF-A
and FGF-2 levels were affected by CS exposure, but
the levels were similarly affected in Ptx3 KO and WT
mice. Further studies are needed to address if the
affected levels of VEGF-A and FGF-2 modulate angio-
genesis in vivo.
In lungs of patients with COPD, inflammatory
responses play an important role in disease pathogenesis
[39] and formation of lymphoid follicles [40]. In this
murine model, we are able to mimick several hallmarks
of COPD pathogenesis [24,29,30]. In this study, CS
exposure provoked inflammatory cell accumulation and
peribronchial lymphoid aggregate formation, which
appeared to be independent of PTX3. Apparently, the
role of PTX3 in lung inflammation is stimulus depen-
dent. Garlanda et al. described a massive inflammatory
response in lungs of Ptx3 KO mice infected with Aspergil-
lus conidia, compared to WT mice [13]. PTX3 deficiency
was also not critical in terms of neutrophilic
inflammation in the lungs and cytokine profile in a
mouse model of LPS-induced toxicity [13], which is in
accordance with our findings. Recently, Deban et al.
described an interaction of PTX3-released from cells of
bone marrow origin, most likely neutrophils-with
P-selectin thereby dampening P-selectin dependent
leukocyte recruitment [41]. Our data suggest that in
CS-induced inflammation such a negative feedback
mechanism is not implicated, possibly because of the
chronic character of the CS-induced inflammation and
because CS is a mild stimulus for PTX3 induction and
release, when compared to LPS or other stimuli used
in the study by Deban et al. [41]. Importantly, in a
Klebsiella-induced pneumonia model, PTX3 is protec-
tive when a low inoculum is given to the mice but
detrimental when a high inoculum is given [42]. These
different results may reflect varied biological actions of
PTX3 depending on the type and intensity of the
inflammatory stimulus. Additionaly, the role of PTX3
also depends on the involvement of the different
pathogenetic mechanisms, which are known to be
modulated by PTX3 (microbial clearance, complement
activation, P-selectin-dependent leukocyte recruitment
or FGF2-dependent angiogenesis).
Emphysema, a structural disorder of the lung parench-
yma, is another hallmark of COPD. In this study, Lm
values, a measure of airspace enlargement, were not dif-
ferent between the two CS-exposed genotypes. Inflam-
mation, apoptosis/proliferation imbalance and protease/
antiprotease imbalance are the concepts used to explain
the pathogenesis of CS-induced emphysema and were
investigated in this study [3,43]. As mentioned above,
CS-induced inflammatory responses were similar
between WT and Ptx3 KO mice. To investigate the
Table 1 Expression of VEGF-A and FGF-2 upon subacute and chronic air or CS-exposure in lungs of WT and Ptx3 KO
mice
4 weeks
WT-Air WT-CS Ptx3 KO-Air Ptx3 KO-CS
VEGF-A/HPRT mRNA 1.00 ± 0.04 0.72 ± 0.04** 1.13 ± 0.09 0.78 ± 0.03*
FGF-2/HPRT mRNA 1.03 ± 0.03 0.85 ± 0.04* 1.12 ± 0.05 0.87 ± 0.10*
VEGF-A (pg/ml) 610.5 ± 16.8 432.4 ± 18.3*** 506.3 ± 16.4 412.5 ± 18.3**
FGF-2 (pg/ml) 2066.3 ± 44.3 3703.8 ± 120.8*** 1933.8 ± 101.9 3892.5 ± 96.8***
24 weeks
WT-Air WT-CS Ptx3 KO-Air Ptx3 KO-CS
VEGF-A/HPRT mRNA 1.11 ± 0.06 0.76 ± 0.05** 1.11 ± 0.05 0.65 ± 0.05**
FGF-2/HPRT mRNA 1.12 ± 0.02 0.93 ± 0.02** 1.20 ± 0.09 0.89 ± 0.07*
VEGF-A (pg/ml) 527.4 ± 16.0 435.3 ± 17.8** 577.2 ± 10.4 396.00 ± 21.0***
FGF-2 (pg/ml) 1196.1 ± 18.4 1974 ± 62.5*** 1163.7 ± 33.0 1946.8 ± 56.0***
Data are presented as mean ± SEM. WT: wild-type, Ptx3 KO: Ptx3 knockout, CS: cigarette smoke.
* p < 0.05, ** p < 0.01 and *** p < 0.001 versus air-exposed mice of same genotype.
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Figure 5 Effect of subacute (4 weeks) cigarette smoke (CS) exposure and PTX3 deficiency on the cell subsets in bronchoalveolar
lavage (BAL) fluid. (A) Total cell numbers and numbers of (B) neutrophils, (C) macrophages, (D) dendritic cells, (E) CD4+ and (F) CD8+ T-
lymphocytes in WT and Ptx3 KO mice upon 4 weeks exposure to air or CS. Results are expressed as mean ± SEM (N = 10 animals/group; *** p <
0.001). All cell types were enumerated by flow cytometry, except for the neutrophils which were determined by cytospin counts.
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Figure 6 Effect of chronic (24 weeks) cigarette smoke (CS) exposure and PTX3 deficiency on the cell subsets in bronchoalveolar
lavage (BAL) fluid. (A) Total cell numbers and numbers of (B) neutrophils, (C) macrophages, (D) dendritic cells, (E) CD4+ and (F) CD8+
T-lymphocytes in WT and Ptx3 KO mice upon 24 weeks exposure to air or CS. Results are expressed as mean ± SEM (N = 10 animals/group;
*** p < 0.001). All cell types were enumerated by flow cytometry, except for the neutrophils which were determined by cytospin counts.
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apoptosis/proliferation balance, we measured VEGF-A
RNA and protein levels in lung tissue. VEGF-A is
known to maintain the homeostasis of the alveolar com-
partment and therefore, decreased VEGF signalling
affects the pathogenesis of emphysema as described in
human emphysema patients by Kanazawa et al. [44] and
animal models of emphysema by Voelkel et al. [43].
VEGF-A levels decreased in CS-exposed mice indepen-
dently of PTX3. We next examined the protease/anti-
protease balance by measuring MMP-12/TIMP-1 ratios.
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Figure 7 Effect of cigarette smoke (CS) exposure and PTX3 deficiency on peribronchial lymphoid aggregates formation. A-D:
Photomicrographs of lymphoid aggregates in CD3/B220 immunostained lung tissue of 24 weeks air and CS-exposed WT and Ptx3 KO mice
(brown = CD3 positive cells and blue = B220 positive cells). E: Quantification of peribronchial lymphoid aggregates in lung tissue of WT and Ptx3
KO mice upon 24 weeks exposure to air or CS. Data are expressed as mean ± SEM (N = 8 animals/group; * p < 0.05).
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As expected, CS shifted the balance in favor of the pro-
tease, MMP-12. However, MMP-12/TIMP-1 ratios were
not different between WT and Ptx3 KO mice. Taken
together, we conclude that PTX3 deficiency did not
affect CS-induced pulmonary manifestations.
Although PTX3 is mostly described to be produced
locally by resident cells, several peripheral blood inflam-
matory cells including neutrophils also release PTX3 [8],
which might target more distant organs or tissues
besides the lungs. Serum PTX3 behaves as an acute-
phase response protein, because its levels are low in
normal conditions (about 25 ng/ml in the mouse) and
increase moderately to dramatically upon inflammation
and infection, depending on the type of stimulus [8]. In
our study, systemic PTX3 levels increased significantly
but mildly at 1-6 hours after short-time CS exposure.
This could suggest that 3 days CS is a mild stimulus for
PTX3 release, when compared to LPS [11]. In accor-
dance with the study described by Introna et al. [11], we
observed the peak of serum PTX3 shortly after CS expo-
sure and PTX3 levels returned to normal levels at 24 h
after exposure. Since CS exposure induces systemic
PTX3 expression and failure to gain body weight in
mice, we investigated if the body weight changes were
mediated by PTX3. Moreover, PTX3 is also expressed in
adipose tissue and serum PTX3 levels are higher in
genetically obese mice as compared with WT mice [45].
However, the PTX3 deficiency had no effect on the
CS-induced failure to gain weight.
Cardiovascular disease contributes significantly to
morbidity and mortality in patients with COPD [46].
COPD is associated with chronic systemic inflammation
which may contribute to the increased risk of cardiovascu-
lar events. C-reactive protein (CRP) is a short pentraxin
C Air-exposed Ptx3 KO (Lm: 39.7 ± 0.9 µm) D CS-exposed Ptx3 KO (Lm: 41.9 ± 1.1 µm)
A Air-exposed WT (Lm: 39.2 ± 0.8 µm) B CS-exposed WT (Lm: 42.9 ± 1.1 µm)
Figure 8 Effect of cigarette smoke (CS) exposure and PTX3 deficiency on pulmonary emphysema. (A-D) Photomicrographs of
hematoxylin and eosin stained lung tissue of 24 weeks air-and CS-exposed WT and Ptx3 KO mice. Lm (mean linear intercept) results are
expressed as mean ± SEM (N = 8 animals/group).
Table 2 Expression of MMP-12 and TIMP-1 upon
subacute and chronic air or CS-exposure in lungs of WT
and Ptx3 KO mice
4 weeks
WT-Air WT-CS Ptx3
KO-Air
Ptx3
KO-CS
MMP-12/HPRT
mRNA
0.11 ±
0.14
1.91 ±
0.43**
0.09 ±
0.01
1.56 ±
0.17**
TIMP-1/HPRT mRNA 0.44 ±
0.05
1.47 ± 0.32* 0.45 ±
0.03
1.12 ±
0.06**
Ratio MMP-12/
TIMP-1
0.25 1.30 0.2 1.39
24 weeks
WT-Air WT-CS Ptx3
KO-Air
Ptx3
KO-CS
MMP-12/HPRT
mRNA
0.10 ±
0.01
1.66 ±
0.16**
0.10 ±
0.01
1.91 ±
0.43**
TIMP-1/HPRT mRNA 0.72 ±
0.10
1.34 ±
0.10**
0.56 ±
0.05
1.20 ±
0.10**
Ratio MMP-12/
TIMP-1
0.14 1.24 0.18 1.60
Data are presented as mean ± SEM. WT: wild-type, Ptx3 KO: Ptx3 knockout,
CS: cigarette smoke.
* p < 0.05 and ** p < 0.01 versus air-exposed mice of same genotype.
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used as serum biomarker of systemic inflammation in
COPD and increased levels of high sensitivity CRP in
serum of patients with COPD have been associated with
increased mortality [47]. The prototypic long pentraxin
PTX3 is also associated with cardiovascular disease inde-
pendently of CRP [48]. PTX3 is, in contrast with CRP,
highly conserved between mice and humans and might
therefore be associated with cardiovascular disease in
COPD. However in this study, systemic PTX3 levels are
only mildly upregulated in CS-exposed mice. Moreover,
CS exposure alone is not sufficient to induce atherosclero-
tic lesions in mice (Pieter Hiemstra, personal communica-
tion). Double-knockout mice lacking PTX3 and
apolipoprotein E (ApoE) in combination with an athero-
genic diet are susceptible for atherosclerosis [36]. In future
work, the contribution of CS-exposure to the development
of atherosclerosis in Ptx3/ApoE double KO mice has to be
elucidated.
Conclusions
Cigarette smoke induce in vivo PTX3 expression in lung
endothelial cells of veins in an IL-1 dependent manner.
CS exposure also rapidly and transiently enhance sys-
temic PTX3 expression. However, PTX3 deficiency is
not critical in CS-induced pulmonary inflammation,
peribronchial lympoid neogenesis, emphysema and body
weight changes in this murine model of COPD.
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